Chan

Alercell's Latest Intellectual Property In-License Bolsters Leukemia Diagnostic Test Advancements

Retrieved on: 
Wednesday, October 25, 2023
Leukemia, Patent, Therapy, Assistant, Oncology, Doctor of Philosophy, Columbia University Vagelos College of Physicians and Surgeons, Cell, TED, Physician, Chan, Columbia University, Classification, Patient, Diagnosis, Edward, Pharmaceutical industry, Surgeon, MD, Medicine

Under the license agreement, Alercell will spearhead the development of a novel diagnostic test for Leukemia which uses terminal erythroid differentiation (TED) as a clinically significant indicator for prognostic classification in patients with myeloid malignancies.

Key Points: 
  • Under the license agreement, Alercell will spearhead the development of a novel diagnostic test for Leukemia which uses terminal erythroid differentiation (TED) as a clinically significant indicator for prognostic classification in patients with myeloid malignancies.
  • Frederic Scheer, the Chief Executive Officer of Alercell, expressed immense enthusiasm regarding this patent license agreement, stating, "We are delighted to license this intellectual property from Columbia University.
  • At Alercell, our mantra is 'knowing before it is too late,' and licensing rights to the patent aligns seamlessly with our unwavering commitment."
  • Alercell's license agreement with Columbia University marks a significant stride for Alercell in the realm of cancer diagnostics, reinforcing the company's dedication to ushering in groundbreaking advancements in the field.

ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration

Retrieved on: 
Thursday, January 19, 2023
Oncology, FDA, Health, Clinical Trials, General Health, Biotechnology, Dor, Survival rate, DCR, Chan, OS, ASCO, Agency, PFS, NMIBC, RECIST, Medicine, Cohort study, Safety, Pancreatic cancer, Hoag (health network), Maintenance, NK, BLA, College, Patient, Radiation, Mortality, ORR, Society, BCG, Progression-free survival, PDUFA, Pharmaceutical industry, ImmunityBio

The results were presented at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) conference in San Francisco January 19-21.

Key Points: 
  • The results were presented at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) conference in San Francisco January 19-21.
  • In subjects with CA 19-9 levels less than 4120 IU/ml (N=40), the median OS was 6.9 months (95% CI: 5.7,10.9).
  • The Agency advised the company to conduct randomized trials in metastatic BCG-unresponsive NMIBC papillary disease and in late-stage metastatic pancreatic cancer.
  • Today, surgery and subsequent adjuvant chemotherapy are the preferred treatment options for pancreatic cancer, but the five-year survival rate for late-stage cases is just 3%.

LPL Financial and Perennial Financial Services Welcome Eddie Chan

Retrieved on: 
Thursday, July 28, 2022
Black Monday, Goal, RIA, GLOBE, LPL Financial, SEC, Partnership, Solution, Intention, Family, Ameriprise Financial, LPL, Technology, Broker-dealer, Business development, Chan, Financial plan, Nasdaq, Communication, LPLA, Perennial plant, Financial adviser

CHARLOTTE, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq:LPLA)announced today that financial advisor Eddie Chan has joined LPL Financials broker-dealer, RIA and custodial platforms, affiliating with Perennial Financial Services , an existing firm supporting LPL-affiliated advisors.

Key Points: 
  • CHARLOTTE, N.C., July 28, 2022 (GLOBE NEWSWIRE) -- LPL Financial LLC (Nasdaq:LPLA)announced today that financial advisor Eddie Chan has joined LPL Financials broker-dealer, RIA and custodial platforms, affiliating with Perennial Financial Services , an existing firm supporting LPL-affiliated advisors.
  • Chan reported having served approximately $110 million in advisory, brokerage and retirement plan assets,* and joins LPL from Ameriprise Financial.
  • John Petrick, senior managing director at Perennial Financial Services, stated, Its an honor and a privilege to welcome Eddie to our expanding family of advisors here at Perennial.
  • Perennial Financial Services, Perennial Investment Advisors and LPL Financial are separate entities.

AssetMark Appoints Christian Chan as Chief Investment Officer

Retrieved on: 
Monday, April 11, 2022
Leadership, Research, Chan, U.S. Securities and Exchange Commission, Technology, AUM, Investment, GLOBE, EFront Alternative Investment Solutions, Solution, Jimmy McNatt, History, Security (finance), Financial adviser

CONCORD, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- AssetMark, a leading provider of wealth management and technology solutions for financial advisors, announced it has appointed Christian Chan, CFA as Chief Investment Officer.

Key Points: 
  • CONCORD, Calif., April 11, 2022 (GLOBE NEWSWIRE) -- AssetMark, a leading provider of wealth management and technology solutions for financial advisors, announced it has appointed Christian Chan, CFA as Chief Investment Officer.
  • In this role, Chan will oversee the investment management and research teams responsible for the full suite of AssetMark-managed solutions, representing $24.7B in AUM.
  • Chan will drive the continual innovation of the AssetMark investment platform, overseeing the management and creation of client-centric, outcome-oriented investment offerings across asset classes.
  • AssetMark currently offers a range of strategies backed by extensive research and experienced investment professionals, exclusively offered to AssetMark advisors and their clients.

The Access to Advanced Health Institute Receives $26 Million Donation from the Chan Soon-Shiong Family Foundation to Further Develop Immune-Enhancing Platform Technology

Retrieved on: 
Monday, April 11, 2022
Other Health, Research, General Health, Pharmaceutical, Philanthropy, Infectious Diseases, Foundation, Science, Biotechnology, Other Philanthropy, Other Science, Health, LinkedIn, Temperature, Vaccination, Infectious Disease Research Institute, Degenerative disease, Clinical trial, Growth, Coronavirus, Access, Culture, Geography, Vaccine, Research, Fungus, Parasitism, MPH, Chan, Cancer, CEO, RNA, Immunity, Health, Immune system, Technology, RNA transfection, COVID-19, Allergy, Infection, Science, Solution, COVID, Patient, Disease, Immunization, Pharmaceutical industry, MD

This catalytic funding will allow AAHIs dedicated team of expert and innovative scientists to combat the worlds deadliest diseases.

Key Points: 
  • This catalytic funding will allow AAHIs dedicated team of expert and innovative scientists to combat the worlds deadliest diseases.
  • AAHIs formulations and RNA immune-enhancing platforms enable more potent, broadly effective, and longer lasting vaccines and immunotherapies by improving the bodys natural response to disease.
  • AAHIs adjuvant and RNA technology can be applied to infectious diseases, cancer, allergies, fungal and parasitic infections, and other non-communicable diseases.
  • Our proprietary design and product development capabilities make safe and effective solutions more affordable, customizable, and faster and easier to mass produce.

CrossCountry Consulting Expands New York Accounting Advisory Leadership Team

Retrieved on: 
Wednesday, February 2, 2022
Growth, Risk, Initial public offering, PricewaterhouseCoopers, Organization, Roman Catholic Diocese of La Crosse, Goal, Technology, CrossCountry, Publishing, Chan, Acquisition, IPO, Accounting, Construction, Financial services, Sales

MCLEAN, Va., Feb. 2, 2022 /PRNewswire/ -- CrossCountry Consulting, a leading business advisory firm , today announced that technical accounting and capital markets expert Iris Chan has been appointed Partner in the firm's New York office.

Key Points: 
  • MCLEAN, Va., Feb. 2, 2022 /PRNewswire/ -- CrossCountry Consulting, a leading business advisory firm , today announced that technical accounting and capital markets expert Iris Chan has been appointed Partner in the firm's New York office.
  • Her hands-on approach to assisting clients with complex technical accounting matters and capital market transactions including IPOs, special purpose acquisition companies (SPACs), and divestiture and merger situations greatly expands the depth of CrossCountry's Accounting Advisory services in the New York market.
  • Iris's experience and expertise will serve to greatly enhance CrossCountry's delivery of these services in the dynamic New York region," said Bruce Klein, New York Office Lead at CrossCountry Consulting.
  • CrossCountry Consultingis a trusted business advisory firm that provides customized finance, accounting, human capital management, risk, operations and technology consulting services to leading organizations facing complex change.

Announcement of Upcoming Launch of Access to Advanced Health Institute and The AAAH Coalition

Retrieved on: 
Wednesday, January 19, 2022
Oncology, Health, Infectious Diseases, General Health, Research, Science, Research, Coalition, Infectious Disease Research Institute, Health, University of Cape Town, Access, Patrick Soon-Shiong, Science, CEO, Emory University, Solution, Disease, Chan, Baylor University, GMP, Goal, Compassion, University of the Witwatersrand, Stellenbosch University, NantWorks, Advance healthcare directive, MPH, AAAH, University, COVID, Pharmaceutical industry, MD

Today the Access to Advanced Health Institute (AAHI) announced its upcoming launch and central role in a new global coalition, Africas Access to Advanced Healthcare (AAAH).

Key Points: 
  • Today the Access to Advanced Health Institute (AAHI) announced its upcoming launch and central role in a new global coalition, Africas Access to Advanced Healthcare (AAAH).
  • The AAAH Coalition is supported through several billion rand funding from Patrick Soon-Shiong, MD, Chairman and Chief Executive Officer of NantWorks, and from the Chan Soon-Shiong Family Foundation.
  • With the technologies and facilities AAHI brings to the AAAH coalition, we can transform that commitment into real change for the people of Africa."
  • Our name, Access to Advanced Health Institute, reflects our ongoing emphasis on advancing science that enables global access to effective, efficient, broad, and durable preventive and therapeutic solutions.

ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival

Retrieved on: 
Tuesday, January 18, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Hoag (health network), Treatment of lung cancer, Mortality, Private Securities Litigation Reform Act, SEC, Ix, NASDAQ, Chan, Infection, PFS, Cancer, NMIBC, Cohort study, Vii, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Mergers and acquisitions, Safety, COVID-19 vaccine, Disease, CIS, Pancreatic cancer, Interleukin, Food, Medicine, FDA, Maintenance, U.S. Securities and Exchange Commission, College, Survival, Forward-looking statement, Patient, Society, Radiation, Progression-free survival, Time, HIV, Therapy, OS, RNA transfection, ORR, III, RECIST, Survival rate, DCR, Dor, Severe acute respiratory syndrome coronavirus 2, GMP, BCG, Pharmaceutical industry, Vaccine, ImmunityBio

Surgery and subsequent adjuvant chemotherapy are the preferred treatment options for pancreatic cancer today, but the five-year survival rate for late-stage cases is just 3% .

Key Points: 
  • Surgery and subsequent adjuvant chemotherapy are the preferred treatment options for pancreatic cancer today, but the five-year survival rate for late-stage cases is just 3% .
  • The median overall survival in this highly advanced group of patients, who failed two to six prior lines of treatment, is 5.8 months (95% CI: 3.9, 6.9 months) exceeding the approximately three-month historical median overall survival.
  • Median overall survival in this group was 6.3 months (95% CI: 5.0, 9.8 months), more than doubling the historical overall survival.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

Retrieved on: 
Thursday, November 11, 2021
Qiagen, Chan, Drug development, Cancer, Therapy, Ingenuity, Toxic epidermal necrolysis, NASDAQ, Immunology, Entelo, CA, Tumor microenvironment, Novel, Amgen, Doctor of Philosophy, Stanford University, CDO, NYSE, QGEN, UCLA, Pharmaceutical industry

BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ --Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer.

Key Points: 
  • BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ --Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer.
  • Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer.
  • "Chan has significant experience advancing novel cancer therapies into clinical development," said Christopher Thanos, Ph.D., Chief Executive Officer of Actym Therapeutics.
  • Actym Therapeutics, based in Berkeley, CA, is a privately-held biotechnology company focused on discovery and development of novel immuno-oncology therapies to treat cancer.

Urovant Sciences Announces Leadership Appointments to Drive Future Growth and Geographic Expansion

Retrieved on: 
Monday, October 18, 2021
Biotechnology, Pharmaceutical, Health, Program, Neurology, OAB, AstraZeneca, FDA, University, Overactive bladder, Therapy, Sarepta Therapeutics, Auburn University, NYSE, Patient, Intellectual property, VideoRay UROVs, Western University, Patent, Urinary incontinence, Uterine fibroid, Allergan, Brandman University, Man, Vibegron, Sumitomo Dainippon Pharma, Public relations, Biology, Chan, Bausch Health, MBA, Urologic disease, Industry, Bachelor of Science in Human Biology, Adult, Bachelor of Arts in Applied Psychology, Marketing, News, University of Victoria, Private practice, Biovail, University of Bologna, Management, Pharmaceutical industry, Fine chemical, Urovant Sciences, Sumitovant Biopharma Ltd., Sumitomo Dainippon Pharma Co., Ltd., UROVANT SCIENCES, SUMITOVANT BIOPHARMA LTD., SUMITOMO DAINIPPON PHARMA CO., LTD.

Genatossio, Darden Powell and Niemaszek join the Urovant Sciences executive leadership team and report to Urovant Sciences President and Chief Executive Officer James Robinson.

Key Points: 
  • Genatossio, Darden Powell and Niemaszek join the Urovant Sciences executive leadership team and report to Urovant Sciences President and Chief Executive Officer James Robinson.
  • I am very pleased to welcome Laura Genatossio to Urovant Sciences to lead our companys ambitious plans to expand our corporate presence in Europe.
  • This is an exciting time for all of us at Urovant Sciences, and our newly appointed senior leadership team members at Urovant will help drive our companys growth and evolution so that we may bring medical breakthroughs to more patients around the world.
  • Darden Powell will be responsible for leading the Urovant Sciences internal and external corporate communications programs and serves as a member of the Urovant executive leadership team.